CEO's Trust Pays $10.7M to Cancel Forward Sale Contract, Unpledging 750K Shares
Summary
Fulgent Genetics CEO Ming Hsieh's trust paid $10.7 million to cancel a prepaid variable forward agreement, regaining control of 750,000 shares previously subject to a future sale obligation.
Key Events
-
Forward Sale Contract Canceled
CEO Ming Hsieh's trust canceled a prepaid variable forward agreement for 750,000 shares that was established in August 2023.
-
$10.7 Million Payment
The trust paid an aggregate of $10,708,875 to an unaffiliated bank to terminate the agreement.
-
Shares Unpledged
The 750,000 shares previously subject to the forward contract are no longer pledged, returning full control to the trust.
Analysis
This Form 4 filing reveals a significant action by CEO Ming Hsieh's trust, which paid $10.7 million to cancel a prepaid variable forward agreement. This cancellation effectively unpledges 750,000 shares that were previously subject to a future selling obligation, removing a potential overhang on the stock. The substantial financial commitment to regain control of these shares signals strong confidence from the CEO in Fulgent Genetics' long-term prospects, especially as it follows recent negative Q4 earnings and outlook disclosures.
At the time of this filing, FLGT was trading at $14.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $448.8M. The 52-week trading range was $13.46 to $31.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.